MX2010013275A - Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano. - Google Patents

Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.

Info

Publication number
MX2010013275A
MX2010013275A MX2010013275A MX2010013275A MX2010013275A MX 2010013275 A MX2010013275 A MX 2010013275A MX 2010013275 A MX2010013275 A MX 2010013275A MX 2010013275 A MX2010013275 A MX 2010013275A MX 2010013275 A MX2010013275 A MX 2010013275A
Authority
MX
Mexico
Prior art keywords
salt
uracil compound
inhibitory activity
group
carbon atoms
Prior art date
Application number
MX2010013275A
Other languages
English (en)
Inventor
Masayoshi Fukuoka
Tatsushi Yokogawa
Seiji Miyahara
Hitoshi Miyakoshi
Wakako Yano
Junko Taguchi
Yayoi Takao
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2010013275A publication Critical patent/MX2010013275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto de uracilo o una sal del mismo, que tiene una potente actividad inhibidora de dUTPasa de humano y es útil, por ejemplo, como un fármaco antitumoral; un compuesto de uracilo representado por la fórmula general (I) o una sal del mismo: (Ver fórmula I) en donde n representa un entero de 1 a 3; X representa un enlace, un átomo de oxígeno, un átomo de azufre, o similar; Y representa un grupo alquileno lineal o ramificado que tiene 1 a 8 átomos de carbono, o similares; y z representa -SO2NR1R2 o -NR3SO2-R4, en donde R1 y R2 cada uno representa un grupo alquilo con 1 a 6 átomos de carbono, un grupo aralquilo que se sustituye opcionalmente, o similares; R3 representa un grupo alquilo con 1 a 6 átomos de carbono, o similares; y R4 representa un grupo hidrocarburo aromático, un grupo heterocíclico insaturado, o similares.
MX2010013275A 2008-06-03 2009-06-02 Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano. MX2010013275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008146334 2008-06-03
PCT/JP2009/002481 WO2009147843A1 (ja) 2008-06-03 2009-06-02 ヒトデオキシウリジントリホスファターゼ阻害活性を有する新規ウラシル化合物又はその塩

Publications (1)

Publication Number Publication Date
MX2010013275A true MX2010013275A (es) 2011-03-15

Family

ID=41397926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010013275A MX2010013275A (es) 2008-06-03 2009-06-02 Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.

Country Status (21)

Country Link
US (1) US8530490B2 (es)
EP (1) EP2295414B1 (es)
JP (1) JP4688975B2 (es)
KR (1) KR101384940B1 (es)
CN (1) CN102056905B (es)
AU (1) AU2009254656B2 (es)
BR (1) BRPI0913590B1 (es)
CA (1) CA2726579C (es)
CY (1) CY1113244T1 (es)
DK (1) DK2295414T3 (es)
ES (1) ES2392220T3 (es)
HK (1) HK1154385A1 (es)
HR (1) HRP20120820T1 (es)
MX (1) MX2010013275A (es)
MY (1) MY149180A (es)
PL (1) PL2295414T3 (es)
PT (1) PT2295414E (es)
RU (1) RU2495873C2 (es)
SI (1) SI2295414T1 (es)
TW (1) TWI466871B (es)
WO (1) WO2009147843A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883759B2 (en) * 2009-11-30 2014-11-11 Taiho Pharmaceutical Co., Ltd. Anti-tumor effect potentiator
SG10202010626PA (en) * 2011-03-31 2020-11-27 Schaefer Konstanze Perfluorinated compounds for the non-viral transfer of nucleic acids
US9809571B2 (en) 2013-01-07 2017-11-07 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2015103489A1 (en) 2014-01-03 2015-07-09 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
WO2016175324A1 (ja) * 2015-04-30 2016-11-03 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
WO2016178416A1 (ja) 2015-05-01 2016-11-10 大鵬薬品工業株式会社 ウラシル化合物の新規結晶
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
EA037990B1 (ru) 2015-07-08 2021-06-21 Св6 Терапьютикс (Най) Лимитед Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US11612653B2 (en) 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098209A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
BR112022026247A2 (pt) 2020-06-26 2023-01-17 Cv6 Therapeutics Ni Ltd Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
CN111763176A (zh) * 2020-07-10 2020-10-13 常州制药厂有限公司 一种GnRH受体拮抗剂关键中间体及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
ATE245631T1 (de) * 1995-03-29 2003-08-15 Taiho Pharmaceutical Co Ltd Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
RU2102390C1 (ru) * 1996-06-06 1998-01-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством МЗМП России N-(6-метил-2,4-диоксо-1,2,3,4-тетрагидропиримидинил-5-сульфонил) пиразин-2-карбоксамид, обладающий противолепрозной, противотуберкулезной и иммунотропной активностью, способ его получения
JP2002028486A (ja) * 2000-07-14 2002-01-29 Toyobo Co Ltd アルデヒド類吸着分解剤及びその製造方法
JP2002284686A (ja) * 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
AU2003218933A1 (en) 2002-04-17 2003-11-03 Affinium Pharmaceuticals, Inc. Purified dutpase from helicobacter pylori
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
JP4534122B2 (ja) * 2003-12-26 2010-09-01 トヨタ自動車株式会社 ハイブリッドシステム
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
WO2008016522A2 (en) * 2006-07-24 2008-02-07 Gilead Sciences, Inc. Hiv reverse transcriptase inhibitors
US8883759B2 (en) * 2009-11-30 2014-11-11 Taiho Pharmaceutical Co., Ltd. Anti-tumor effect potentiator

Also Published As

Publication number Publication date
CY1113244T1 (el) 2016-04-13
BRPI0913590B1 (pt) 2021-07-06
AU2009254656B2 (en) 2013-07-18
ES2392220T3 (es) 2012-12-05
US20110082163A1 (en) 2011-04-07
KR101384940B1 (ko) 2014-04-11
EP2295414A1 (en) 2011-03-16
AU2009254656A2 (en) 2011-01-13
KR20110013427A (ko) 2011-02-09
RU2010154425A (ru) 2012-07-20
BRPI0913590A2 (pt) 2015-10-20
CN102056905B (zh) 2014-03-26
TW201000452A (en) 2010-01-01
EP2295414A4 (en) 2011-09-14
PT2295414E (pt) 2012-11-30
HRP20120820T1 (hr) 2012-11-30
CA2726579A1 (en) 2009-12-10
HK1154385A1 (en) 2012-04-20
DK2295414T3 (da) 2012-10-22
SI2295414T1 (sl) 2012-12-31
JP4688975B2 (ja) 2011-05-25
PL2295414T3 (pl) 2013-02-28
US8530490B2 (en) 2013-09-10
AU2009254656A1 (en) 2009-12-10
TWI466871B (zh) 2015-01-01
EP2295414B1 (en) 2012-09-26
WO2009147843A1 (ja) 2009-12-10
CA2726579C (en) 2015-02-17
RU2495873C2 (ru) 2013-10-20
JPWO2009147843A1 (ja) 2011-10-27
MY149180A (en) 2013-07-31
CN102056905A (zh) 2011-05-11

Similar Documents

Publication Publication Date Title
MX2010013275A (es) Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
TW200642683A (en) Heterocyclic compound
IL204621A (en) Amino Acid Derivatives - γ - In bicycles preparations containing them and their uses
DE60301345D1 (de) Stabilisierte askorbinsäurederivate
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MX2010001240A (es) Derivado de oxopirazina y herbicida.
MY177250A (en) Novel nicotinamide derivative or salt thereof
WO2008108380A3 (en) Pyrrole compounds
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
MY152972A (en) Azabicyclo compound and salt thereof
MX2009010024A (es) Nuevo compuesto de adenina.
TW200745034A (en) New compounds
IN2014CN03976A (es)
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
NZ596615A (en) Substituted isoquinoline derivative
MX2010008637A (es) Derivado de fenilpirrol novedoso.
MX2011009423A (es) Compuesto de piperazina capaz de inhibir prostaglandina d sintasa.
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
WO2009047298A3 (en) Dimers of harmol or of its derivatives and uses thereof
EP1634874A4 (en) imidazolidine
TW200637870A (en) Novel pyrimidine nucleoside compound and salt thereof
TW200714593A (en) Agent for treatment of solid tumor
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.

Legal Events

Date Code Title Description
FG Grant or registration